

Impact of Untreated Obstructive Sleep Apnea on Glucose Control in Type 2 Diabetes

Renee S. Aronsohn MD, Harry Whitmore BA, RPSGT,
Eve Van Cauter PhD and Esra Tasali MD

Department of Medicine, The University of Chicago, Chicago, IL

Running Title: Sleep Apnea and Type 2 Diabetes

Address for correspondence and requests for reprints:

Renee Aronsohn, M.D.
Department of Medicine, MC 1027
University of Chicago
5841 South Maryland Avenue
Chicago, IL 60637
Tel: (773) 702-5909
Fax: (773) 834-0486
E-mail: raronsoh@medicine.bsd.uchicago.edu

AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject

Obstructive sleep apnea is associated with alterations in glucose metabolism in non-diabetic individuals and is a highly prevalent co-morbidity of type 2 diabetes, but its effect on glycemic control in diabetic patients is not known.

What This Study Adds to the Field

In patients with type 2 diabetes, there is a robust graded relationship between the severity of obstructive sleep apnea and glycemic control, after controlling for the degree of adiposity and other confounders.

Word count: 3711

Descriptor number: 15.10 (Sleep: Other)

This work was supported by the National Institute of Health Grants P01 AG11412, P60 DK20595, and R01 HL086459, and grants from AASM/Pfizer Scholars Grant in Sleep Medicine and the ResMed Foundation. The funding sources had no role in the study design or concept; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.

ABSTRACT

Rationale: Obstructive sleep apnea (OSA), a treatable sleep disorder that is associated with alterations in glucose metabolism in non-diabetic individuals, is a highly prevalent co-morbidity of type 2 diabetes. However, it is not known whether the severity of OSA is a predictor of glycemic control in diabetic patients.

Objective: To determine the impact of OSA on hemoglobin A1c (HbA1c), the major clinical indicator of glycemic control, in patients with type 2 diabetes.

Methods: We performed polysomnography studies and measured HbA1c in 60 consecutive diabetic patients recruited from outpatient clinics between February 2007 and August 2009.

Measurements and Main Results: Seventy-seven percent of diabetic patients had OSA (apnea-hypopnea index [AHI] ≥ 5). Increasing OSA severity was associated with poorer glucose control, after controlling for age, sex, race, BMI, number of diabetes medications, level of exercise, years of diabetes and total sleep time. Compared to patients without OSA, the adjusted mean HbA1c was increased by 1.49% ($p=0.0028$) in patients with mild OSA, 1.93% ($p=0.0033$) in patients with moderate OSA, and 3.69% ($p<0.0001$) in patients with severe OSA ($p<0.0001$ for linear trend). Measures of OSA severity, including total AHI ($p=0.004$), REM AHI ($p=0.005$), and the oxygen desaturation index during total and REM sleep ($p=0.005$ and $p=0.008$, respectively) were positively correlated with increasing HbA1c levels.

Conclusions: In patients with type 2 diabetes, increasing severity of OSA is associated with poorer glucose control, independent of adiposity and other confounders, with effect sizes comparable to those of widely used hypoglycemic drugs.

Word count (Abstract): 237

Key words: sleep disordered breathing; glycemic control; diabetes

INTRODUCTION

Given the enormous public health burden of the type 2 diabetes epidemic and growing concerns about the safety profiles of current pharmacologic treatments [1, 2], a better understanding of the impact of co-morbidities on glucose control is needed to develop additional preventive and therapeutic strategies. Obstructive sleep apnea (OSA) is a treatable sleep disorder characterized by repetitive upper airway closures leading to oxygen desaturations and sleep fragmentation. OSA has been identified as a highly prevalent co-morbidity of type 2 diabetes [3-5]. In particular, among obese type 2 diabetic patients, who represent the vast majority of individuals with type 2 diabetes in the United States, the prevalence has recently been estimated at a staggering 86% [5].

Obstructive sleep apnea is a well-documented risk factor for cardiovascular disease and mortality [6-9]. Multiple epidemiologic and clinical studies have revealed that non-diabetic individuals suffering from OSA show alterations in glucose metabolism including insulin resistance and impaired glucose tolerance, independent of adiposity [10-13].

Despite these independent associations between OSA and abnormal glucose metabolism and the high prevalence of OSA in type 2 diabetic patients, data on whether the presence and severity of OSA compromises glycemic control in patients with type 2 diabetes is lacking. The majority of type 2 diabetic patients need multiple drugs, in addition to lifestyle modifications, to control glucose levels and avoid or delay the development of serious complications [14]. Currently, both physicians and patients are challenged by rising concerns about the safety of widely used pharmacologic treatment options. Therefore, determining whether OSA has an adverse effect on glucose control in diabetic patients has major clinical implications since effective treatment of OSA

could be a non-pharmacologic strategy to improve glucose control in the management of millions of patients with type 2 diabetes.

In the present study, we therefore evaluated the impact of untreated OSA on hemoglobin A1c (HbA1c), the major clinical indicator of glycemic control, in patients with type 2 diabetes. Preliminary findings from this study have been previously reported in abstract form [15, 16].

METHODS

Participants and study design

Patients with type 2 diabetes were consecutively recruited by one of the study investigators, Dr. Renee Aronsohn, from Primary Care and Endocrinology Clinics at the University of Chicago between February 2007 and August 2009. Sleep complaints or symptoms of OSA were not used as selection criteria. All participants were on stable medications for diabetes and other co-morbidities for the preceding 3 months. Subjects were excluded if they failed to meet the criteria for type 2 diabetes, based on physician diagnosis in accordance with established guidelines [14]; or if they had unstable cardiopulmonary, neurological or psychiatric disease; upper airway surgery; or used nocturnal oxygen, positive airway pressure therapy or oral appliances. The study was approved by the University of Chicago Institutional Review Board, and all participants gave written informed consent.

During a 45-minute interview, each patient completed surveys including the University of Chicago Diabetes/Quality of Life Survey [17] (which includes self-report of medications, presence of diabetic complications [retinopathy, nephropathy, neuropathy, coronary artery disease and peripheral vascular disease], and level of exercise

[No=rarely, Mild=once or twice a week, Moderate=three times a week, and Heavy=more than three times a week]), the Berlin Questionnaire [18] (used to assess the presence of snoring) and the Center for Epidemiologic Studies Depression Scale [19] (score ≥ 16 indicates depression). Height and weight were measured in all patients. Waist circumference was measured in 58 patients. Subjects underwent five consecutive days of ambulatory wrist actigraphy to determine habitual sleep habits. An overnight laboratory PSG was then performed to establish the presence and severity of OSA. Bedtimes in the laboratory were individually designed based on the subject's usual habits derived from actigraphy. However, each subject was recorded for a minimum of 7 hours. HbA1c values (% defined as the proportion of hemoglobin that is glycosylated) were obtained from the patient's chart if assessed during the previous 3 months, or a single blood sample was drawn on the morning after PSG. HbA1c was measured by Bio-Rad Variant Classic boronate affinity-automated HPLC (Bio-Rad, Hercules, CA). The intraassay CV was 0.5–1.0%, and the interassay CV ranges from 2.2–2.4%.

Polysomnography

PSG (Neurofax EEG 1100 system, Nihon Kohden, CA) included recordings of six electroencephalogram (EEG) channels, bilateral electrooculograms, chin and tibialis electromyogram, electrocardiogram, airflow by nasal pressure transducer and oronasal thermocouples, chest and abdominal wall motion by piezo electrodes, and oxygen saturation by pulse oximeter. Recordings were visually scored in 30-second intervals in stages 1, 2, 3 and 4 of non-rapid eye movement (REM) sleep and in REM sleep according to standard criteria [20]. Respiratory events and microarousals were scored according to established criteria [21, 22]. Total cessation of airflow for at least 10 seconds was

defined as apnea (obstructive if respiratory efforts were present and central if respiratory efforts were absent). Hypopneas were identified if there was a discernable reduction in airflow lasting at least 10 seconds and associated with $\geq 3\%$ desaturation. The apnea-hypopnea index (AHI) was defined as the total number of obstructive apneas and obstructive hypopneas per hour of sleep. OSA severity categories were defined according to commonly used clinical cut-offs as follows: no OSA (AHI < 5), mild OSA (AHI ≥ 5 but < 15), moderate OSA (AHI ≥ 15 but < 30), and severe OSA (AHI ≥ 30). Total oxygen desaturation index (ODI) was defined as the total number of desaturations of $\geq 3\%$ per total sleep time in hours. REM ODI was defined as number of desaturations of $\geq 3\%$ during REM sleep per REM sleep time in hours. The microarousal index was calculated as the total number of microarousals per hour of sleep.

Actigraphy

Habitual sleep duration was assessed at home by actigraphy using the Actiwatch (Mini-Mitter, Oregon) in accordance with previously described methods [23-25]. Participants were asked to wear the Actiwatch for five consecutive days, three weekdays and two weekend days, and to maintain their habitual bedtimes and fill out daily sleep logs. Of the 60 subjects who were included in the final analysis, 50 (83%) wore the Actiwatch for all 5 days, 7 (12%) wore the Actiwatch for 4 days, and 2 (3%) wore the Actiwatch for 3 days. One subject's data could not be downloaded due to a technical failure, thus data on habitual sleep duration are reported in n=59.

Statistical analysis

Group data are expressed as mean \pm SD. Variables were examined for normality, and if skewed the log-transformed values were used. All categorical data were compared by Pearson's χ^2 test. Pairwise comparisons of continuous variables in patients with and without OSA were examined by t-test and confirmed by the non-parametric Mann-Whitney test. Unadjusted group differences across OSA severity categories were assessed by ANOVA. A linear contrast was used to test for trend. We performed multivariate regression analyses to characterize the independent associations between measures of OSA severity and the primary outcome variable, HbA1c. The primary independent predictor was the OSA severity category and we also examined total AHI, REM AHI, total ODI and REM ODI. Potential confounding variables included in all multivariable models as covariates were: age, sex, race, BMI, number of diabetes medications, level of exercise, years since diabetes diagnosis, and total sleep time by PSG. After log-transformation, the distribution of HbA1c values remained skewed due to one outlier subject, thus a sensitivity analysis excluding this outlier value was performed and confirmed the significance of the association between severity of OSA and HbA1c. We also performed sensitivity analyses using waist circumference as covariate (instead of BMI) in all multivariate models. Data are presented in non-log transformed values for ease of interpretation. All statistical analyses were performed using JMP statistical software (SAS Institute, version 6.0.3). All reported p-values are two sided.

RESULTS

Figure 1 shows the flow diagram of patient recruitment and selection. Patients who obtained less than 4 hours of total sleep time during the PSG, thus preventing

accurate assessment of the degree of severity of OSA, were not included in the analysis (n=6). One patient showed severe oxygen desaturations not explained by apneas or hyponeas (thus consistent with significant hypoventilation) and in another patient, the PSG data could not be interpreted due to multiple artifacts in the airflow signal. Thus, 60 patients were included in the final analysis.

Table 1 summarizes the demographic characteristics of the cohort, which comprised similar proportions of men and women and of Whites and African Americans. The age range was 41 to 77 years. The BMI range was 20 to 57 kg/m². The sample included 7 lean, 14 overweight, and 39 obese patients.

Forty-six of the 60 patients (77%) had OSA (AHI \geq 5). Only 5 patients had been previously evaluated for OSA, and none were receiving treatment. Mild, moderate and severe OSA was found in 38.3% (n=23), 25.0% (n=15), and 13.3% (n=8) of the sample, respectively.

Compared to patients without OSA, those with OSA were heavier and 6 years older on average (**Table 1**). Increasing severity of OSA was associated with increasing BMI (unadjusted p=0.00042 for linear trend) and greater waist circumference (unadjusted p=0.00038 for linear trend). Patients without OSA had fewer diabetic complications than those with OSA. Out of 60 patients, 6 (10%) did not take any diabetes medications (i.e. insulin, oral agents, or incretin-based therapies), 18 (30%) were on 1 medication, 24 (40%) were on 2 medications, 11 (18%) were on 3 medications, and 1 (2%) patient was on 4 medications. Out of 60 patients, 20 (33.3%) reported no exercise, 11 (18.3%) reported mild, 14 (23.3%) reported moderate exercise, and 15 (25.0%) reported heavy exercise.

Sleep characteristics are summarized in **Table 2**. Habitual sleep duration was not significantly different between patients with and without OSA. In the laboratory, patients with OSA had shorter total sleep duration, decreased sleep efficiency, increased wake time after sleep onset, and less REM sleep than those without OSA. Increasing severity of OSA was associated with lower amounts of REM sleep (unadjusted $p=0.012$ for linear trend), more stage 1 sleep (unadjusted $p=0.007$ for linear trend), and more sleep fragmentation as assessed by the microarousal index (unadjusted $p=0.0001$ for linear trend). The predominant respiratory disturbances were obstructive apneas and hypopneas rather than central apneas.

Increasing severity of OSA was associated with poorer glucose control after controlling for age, sex, race, BMI, number of diabetes medications, level of exercise, years of diabetes and total sleep time on PSG ($p<0.0001$ for linear trend). **Figure 2** shows the adjusted mean values of HbA1c in each OSA category. Compared to patients without OSA, the adjusted mean HbA1c was increased by 1.49% ($p=0.0028$) in patients with mild OSA, 1.93% ($p=0.0033$) in patients with moderate OSA, and 3.69% ($p<0.0001$) in patients with severe OSA ($p<0.0001$ for linear trend). Associations between OSA severity and HbA1c levels remained robust when “number of diabetes medications” was replaced by “oral hypoglycemic medication use” ($p<0.0001$ for linear trend) or “insulin use” ($p=0.0002$ for linear trend) in the regression model. Similar associations between the severity of OSA and glycemic control were found when the presence of diabetic complications was added to the regression model ($p<0.0001$ for linear trend). A sensitivity analysis including waist circumference (instead of BMI) in the

regression model also showed similar linear associations between increasing severity of OSA and higher HbA1c levels ($p=0.0001$ for linear trend).

Other measures of OSA severity, including total AHI ($p=0.004$), REM AHI ($p=0.005$), total ODI ($p=0.005$) and REM ODI ($p=0.008$) were positively correlated with increasing HbA1c levels after adjusting for age, sex, race, BMI, number of diabetes medications, level of exercise, years of diabetes and total sleep time on PSG. We did not detect significant associations between HbA1c levels and the microarousal index ($p=0.75$) or the amount of slow wave sleep ($p=0.67$) after adjusting for age, sex, race, BMI, number of diabetes medications, level of exercise, years of diabetes, and total sleep time.

DISCUSSION

The present study indicates that OSA is highly prevalent in patients with type 2 diabetes and demonstrates for the first time a clear, graded, inverse relationship between OSA severity and glucose control in patients with type 2 diabetes, after controlling for the degree of adiposity and multiple other potential confounders. Forty-six of our 60 subjects (77%) had OSA. In nearly 90% of these patients, the presence of OSA had not been previously evaluated. Relative to patients without OSA, the presence of mild, moderate or severe OSA increased mean adjusted HbA1c values by 1.49%, 1.93%, and 3.69%, respectively. These effect sizes are comparable, if not exceeding, to those of widely used hypoglycemic medications [26-28]. Our findings have important clinical implications as they support the hypothesis that reducing the severity of OSA may improve glycemic control. Thus effective treatment of OSA may

represent a novel non-pharmacologic intervention in the management of millions of patients with type 2 diabetes.

Obstructive apneas and hypopneas were more frequent during REM sleep than other sleep stages, indicating that the prevalence and the degree of severity of OSA in patients with type 2 diabetes may be underestimated when recording times are too short to allow for sufficient amounts of REM sleep to occur. Our findings contrast with the negative results of the only previous study that examined associations between the severity of OSA and HbA1c in patients with type 2 diabetes [4]. It is possible that the lack of association in the previous study was due to the short duration of PSG recording (reported to be as low as 4 hours) and thus perhaps insufficient to detect an association between OSA severity and HbA1c. In contrast, our study design specified a minimum duration of PSG recording of 7 hours and our subjects achieved 6.6 hours of sleep on average. Of note, in an exploratory re-analysis of our own data set using only the first 4 hours of recording, the robust relationship between severity of OSA and HbA1c found with a PSG recording time ≥ 7 hours was much weaker. Compared to patients without OSA (mean adjusted HbA1c: 7.05%), when only 4 hours of recording were analyzed, the adjusted mean HbA1c levels were not different in patients with mild OSA (mean adjusted HbA1c: 6.83%; $p=0.67$), moderate OSA (mean adjusted HbA1c: 7.79%; $p=0.28$) and severe OSA (mean adjusted HbA1c: 8.53%; $p=0.10$), indicating that the shorter duration of PSG recording, which precludes observing normal amounts of REM sleep, fails to detect the robust relationship observed with the longer recording time. These findings highlight the importance of obtaining PSG recordings longer than the

commonly used minimum of 4 hours to examine associations between OSA severity and metabolic variables.

In our sample, OSA was characterized by a clear predominance of obstructive, rather than central, disease. This is in contrast with findings from the Sleep Heart Health Study in which self-reported diabetes was associated with a significant increase in periodic breathing, an abnormality reflecting disruption of central control of breathing, and a non-statistically significant increase in the occurrence of central apneas [3]. By contrast, we did not observe periodic breathing pattern in any participant of our sample. Consistent with our findings, two previous studies in diabetic patients with autonomic neuropathy have reported a high frequency of obstructive, rather than central respiratory events [29, 30]. The finding of predominantly obstructive disease in diabetic patients has important clinical implications since it would indicate that the available therapies to improve obstructive disease, such as positive airway pressure therapy, oral appliances, and surgical options, [31] could have a significant effect on glucose control in patients with type 2 diabetes and OSA. To date, six studies including a total number of 120 patients have examined the impact of CPAP treatment of OSA on measures of glucose tolerance in T2DM [32-37]. The study by Babu et al. [32] involving 25 obese diabetic patients showed beneficial effects of 3 months of CPAP use on HbA1c and post-prandial glucose levels, and two other studies [33, 36] reported improvements in nocturnal glucose levels after CPAP. Two earlier studies including only a total of 10 subjects [34, 35] showed no change in HbA1c levels, but reported improvements in insulin sensitivity (by hyperinsulinemic euglycemic clamps) after 3 to 4 months of CPAP. The only randomized controlled study by West et al. [37], which included 20 obese

diabetic patients randomized to the active CPAP arm, found no effect of active CPAP on HbA1c levels or insulin sensitivity, but reported significant improvements in sleepiness measures. Of note, in this study, the average nightly CPAP use over 3 months period was only ~ 3.3 hrs. By contrast, the positive study by Babu et al., found that in patients who used CPAP for more than 4 hrs per night (average nightly use of ~ 6.6 hrs/night), the reduction in HbA1c levels was strongly correlated with CPAP use, suggesting that the negative findings on HbA1c in the study by West et al. could be explained, at least in part, by low CPAP adherence. It is also possible that the efficacy of CPAP varies according to the outcome (i.e. sleepiness versus glucose control) such that the duration and nightly use of CPAP needed to observe significant benefits may not be the same for cognitive versus metabolic outcomes.

Our findings regarding the prevalence of OSA in patients with type 2 diabetes are consistent with those of the most recent and largest study, the Sleep AHEAD study which included 306 obese diabetic patients and reported a prevalence of 86% [5]. Two earlier studies had estimated the prevalence of OSA in patients with type 2 diabetes using full overnight PSG. First, the Sleep Heart Health Study (SHHS) involving older individuals (about 50% more than 65 years of age), in whom the diagnosis of diabetes was based on self report only, found an OSA prevalence of 58% [3]. Further, in the SHHS, the definition of hypopneas was based on at least 4% desaturation, whereas in our study, we used a cut-off of 3% desaturation, which could explain the difference in prevalence estimations [38]. The second study [4], which did not specify respiratory event definitions, reported a prevalence of 71%, similar to our findings. Of note, in an exploratory re-analysis of our data using a definition of hypopneas based on a minimum

of 4% desaturation, the prevalence of OSA was 58% (versus 77% with a cut-off of 3% desaturation) similar to that reported in the SHHS. Importantly, the associations between OSA severity and HbA1c levels that we observed with a cut-off of 3% desaturation remained significant albeit somewhat weaker when the 4% desaturation criteria was used ($p=0.007$ and $p=0.013$ for total AHI and REM AHI, respectively). These findings suggest that the reliance on strict criteria in defining OSA may fail to detect the patients with milder disease who could nonetheless potentially benefit from treatment.

Our study was not designed to examine the mechanisms linking OSA and glucose control in type 2 diabetes. Although it remains possible that hyperglycemia may promote sleep disturbances, the current evidence supports the hypothesis that OSA, and its inherent characteristics such as intermittent hypoxia, elevated sympathetic nervous activity [39, 40], sleep fragmentation and low amounts of SWS [41], and cumulative sleep loss [42, 43], has adverse effects on glucose tolerance. Multiple prospective epidemiologic studies have indicated that short sleep and/or poor sleep quality, as is typical of OSA, is associated with an increased incidence of diabetes over time [44-49]. In a recent prospective population study, the presence of moderate to severe OSA was found to be a significant risk factor for incident diabetes during a 4-year follow-up period [50].

The present study reveals that the majority of type 2 diabetic patients have undiagnosed OSA and that untreated OSA is associated with poorer glucose control, which may instigate the need for more intensive pharmacotherapy. Conversely, treating OSA may have clinically significant beneficial effects on glucose control and reduce the

number of drugs needed and/or their dose regimen. Pharmacotherapy of type 2 diabetes with drugs that promote weight gain may have the undesirable consequence of promoting the development of OSA or exacerbating the severity of existing OSA, thereby compromising glycemic control and elevating cardiovascular risk. The high prevalence of OSA and its cardiovascular consequences in type 2 diabetes may help in understanding possible adverse effects of anti-diabetic pharmacotherapy. Noteworthy examples are the recent findings of the ACCORD and ADVANCE trials that examined the impact of intensive glucose lowering on cardiovascular risk [51, 52]. Based on the data from our study, it is likely that OSA was present in most participants in both trials and that this unrecognized co-morbidity may explain the failure of near-normal glucose control to decrease the incidence of major macrovascular events. Consistent with a putative role of OSA in these findings, the ACCORD trial, which had to be terminated early due to unexpected mortality (particularly from cardiovascular causes), enrolled participants who were on average 15 kg heavier at baseline (thus more likely to have OSA as well as more severe OSA) than those participating in the ADVANCE trial, which did not observe increased mortality or higher incidence of cardiovascular disease. Further, those in the intensive treatment arm of ACCORD gained substantially more weight (more than 10 kg in about one third of the patients) than those in the standard therapy arm while the difference in weight gain between the two treatment arms of ADVANCE was less than 1 kg. It is well documented that weight gain increases the severity of OSA [53, 54] and thus obese participants in the intensive treatment arm of ACCORD may have been at increased risk for more severe OSA, and thus at increased risk for major cardiovascular events and death. Our findings are also noteworthy in the

context of recent reports discussing a possible link between the use and dose of insulin glargine and cancer risk [2]. Although the evidence is inconclusive, the questions raised by these reports clearly highlight the importance of developing additional, non-pharmacologic alternatives to offer patients with type 2 diabetes.

There is a relentless increase in type 2 diabetes worldwide. Diligent control of glucose levels is needed to prevent or delay the development of life-threatening complications. Most patients are treated with multiple drugs, and a substantial proportion require insulin injections. This pharmacotherapy is not without risk and may promote further weight gain. Our findings indicate that the role of OSA in the management of type 2 diabetes is in urgent need of further rigorous assessment. Current practice approach should be updated to include systematic evaluation and treatment of OSA in patients with type 2 diabetes.

REFERENCES

1. Nissen, S.E. and K. Wolski, *Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes*. N Engl J Med, 2007. **356**(24): p. 2457-71.
2. Hemkens, L.G., U. Grouven, R. Bender, C. Gunster, S. Gutschmidt, G.W. Selke, and P.T. Sawicki, *Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study*. Diabetologia, 2009.
3. Resnick, H.E., S. Redline, E. Shahar, A. Gilpin, A. Newman, R. Walter, G.A. Ewy, B.V. Howard, and N.M. Punjabi, *Diabetes and sleep disturbances: findings from the Sleep Heart Health Study*. Diabetes Care, 2003. **26**(3): p. 702-9.
4. Einhorn, D., D.A. Stewart, M.K. Erman, N. Gordon, A. Philis-Tsimikas, and E. Casal, *Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus*. Endocr Pract, 2007. **13**(4): p. 355-62.
5. Foster, G.D., M.H. Sanders, R. Millman, G. Zammit, K.E. Borradaile, A.B. Newman, T.A. Wadden, D. Kelley, R.R. Wing, F.X. Pi Sunyer, V. Darcey, and S.T. Kuna, *Obstructive Sleep Apnea among Obese Patients with Type 2 Diabetes*. Diabetes Care, 2009.
6. Somers, V.K., D.P. White, R. Amin, W.T. Abraham, F. Costa, A. Culebras, S. Daniels, J.S. Floras, C.E. Hunt, L.J. Olson, T.G. Pickering, R. Russell, M. Woo, and T. Young, *Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke*

- Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol, 2008. 52(8): p. 686-717.*
7. Yaggi, H.K., J. Concato, W.N. Kernan, J.H. Lichtman, L.M. Brass, and V. Mohsenin, *Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med, 2005. 353(19): p. 2034-41.*
 8. Young, T., L. Finn, P.E. Peppard, M. Szklo-Coxe, D. Austin, F.J. Nieto, R. Stubbs, and K.M. Hla, *Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep, 2008. 31(8): p. 1071-8.*
 9. Bradley, T.D. and J.S. Floras, *Obstructive sleep apnoea and its cardiovascular consequences. Lancet, 2009. 373(9657): p. 82-93.*
 10. Punjabi, N.M., E. Shahar, S. Redline, D.J. Gottlieb, R. Givelber, and H.E. Resnick, *Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol, 2004. 160(6): p. 521-30.*
 11. Punjabi, N.M. and B.A. Beamer, *Alterations in Glucose Disposal in Sleep-disordered Breathing. Am J Respir Crit Care Med, 2009. 179(3): p. 235-40.*
 12. Seicean, S., H.L. Kirchner, D.J. Gottlieb, N.M. Punjabi, H. Resnick, M. Sanders, R. Budhiraja, M. Singer, and S. Redline, *Sleep Disordered Breathing and Impaired Glucose Metabolism in Normal Weight and Overweight/Obese Individuals: The Sleep Heart Health Study. Diabetes Care, 2008.*
 13. Shaw, J.E., N.M. Punjabi, J.P. Wilding, K.G. Alberti, and P.Z. Zimmet, *Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract, 2008. 81(1): p. 2-12.*

14. *Standards of medical care in diabetes--2009*. Diabetes Care, 2009. **32 Suppl 1**: p. S13-61.
15. Aronsohn R, W.H., Young T, Van Cauter E, Tasali E., *The Impact of Untreated Obstructive Sleep Apnea on Glucose Control in Type 2 Diabetes*. 23rd Associated Professional Sleep Societies Meeting, Seattle, WA 2009, 2009.
16. Aronsohn R, W.H., Young T, Van Cauter E, Tasali E, *The Impact of Untreated Obstructive Sleep Apnea on Glucose Control in Type 2 Diabetes*. 69th American Diabetes Association Meeting, New Orleans, LA, 2009.
17. Meltzer, D. and B. Egleston, *How patients with diabetes perceive their risk for major complications*. Eff Clin Pract, 2000. **3(1)**: p. 7-15.
18. Netzer, N.C., R.A. Stoohs, C.M. Netzer, K. Clark, and K.P. Strohl, *Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome*. Ann Intern Med, 1999. **131(7)**: p. 485-91.
19. Radloff, L., *The CES-D Scale: a self-report depression scale for research in the general population*. Appl Psychol Meas, 1977. **1**: p. 385-401.
20. Rechtschaffen, A. and A. Kales, *A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects*. 1968, UCLA Brain Information Service/Brain Research Institute, Los Angeles.
21. *EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association*. Sleep, 1992. **15(2)**: p. 173-184.
22. *Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an*

- American Academy of Sleep Medicine Task Force. Sleep, 1999. 22(5): p. 667-689.*
23. Knutson, K.L., P.J. Rathouz, L.L. Yan, K. Liu, and D.S. Lauderdale, *Intra-individual daily and yearly variability in actigraphically recorded sleep measures: the CARDIA study. Sleep, 2007. 30(6): p. 793-6.*
24. Lauderdale, D.S., K.L. Knutson, L.L. Yan, P.J. Rathouz, S.B. Hulley, S. Sidney, and K. Liu, *Objectively measured sleep characteristics among early-middle-aged adults: the CARDIA study. Am J Epidemiol, 2006. 164(1): p. 5-16.*
25. Jean-Louis, G., H. von Gizycki, F. Zizi, A. Spielman, P. Hauri, and H. Taub, *The actigraph data analysis software: I. A novel approach to scoring and interpreting sleep-wake activity. Percept Mot Skills, 1997. 85(1): p. 207-16.*
26. Duckworth, W., M. Marcelli, M. Padden, K. Kellick, T. Duhancik, M. Wilhardt, K. Colgan, and A. Romie, *Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm, 2003. 9(3): p. 256-62.*
27. Garber, A.J., D.S. Donovan, Jr., P. Dandona, S. Bruce, and J.S. Park, *Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab, 2003. 88(8): p. 3598-604.*
28. Amori, R.E., J. Lau, and A.G. Pittas, *Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Jama, 2007. 298(2): p. 194-206.*

29. Bottini, P., S. Redolfi, M.L. Dottorini, and C. Tantucci, *Autonomic neuropathy increases the risk of obstructive sleep apnea in obese diabetics*. Respiration, 2008. **75**(3): p. 265-71.
30. Bottini, P., M.L. Dottorini, M. Cristina Cordoni, G. Casucci, and C. Tantucci, *Sleep-disordered breathing in nonobese diabetic subjects with autonomic neuropathy*. Eur Respir J, 2003. **22**(4): p. 654-60.
31. Sanders, M., *Sleep Breathing Disorders*, in *Principles and Practice of Sleep Medicine*, M. Kryger, T. Roth, and W.C. Dement, Editors. 2005, W.B Saunders Company: Philadelphia. p. 969-1157.
32. Babu, A.R., J. Herdegen, L. Fogelfeld, S. Shott, and T. Mazzone, *Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea*. Arch Intern Med, 2005. **165**(4): p. 447-52.
33. Dawson, A., S.L. Abel, R.T. Loving, G. Dailey, F.F. Shadan, J.W. Cronin, D.F. Kripke, and L.E. Kline, *CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep*. J Clin Sleep Med, 2008. **4**(6): p. 538-42.
34. Harsch, I.A., S.P. Schahin, K. Bruckner, M. Radespiel-Troger, F.S. Fuchs, E.G. Hahn, P.C. Konturek, T. Lohmann, and J.H. Ficker, *The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes*. Respiration, 2004. **71**(3): p. 252-9.
35. Brooks, B., P.A. Cistulli, M. Borkman, G. Ross, S. McGhee, G. R.R., C.E. Sullivan, and D.K. Yue, *Obstructive sleep apnea in obese noninsulin-dependent*

- diabetic patients: Effects of continuous positive airway pressure treatment on insulin responsiveness.* J Clin Endocrinol Metab, 1994. **79**: p. 1681-1685.
36. Pallayova, M., D. Donic, V. Donicova, and Z. Tomori, *Effect of continuous positive airway pressure on nocturnal glucose levels in type 2 diabetics with sleep apnea: Results of continuous glucose monitoring.* Sleep Medicine, 2006. **7**, **Suppl2** p. S50.
37. West, S.D., D.J. Nicoll, T.M. Wallace, D.R. Matthews, and J.R. Stradling, *Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes.* Thorax, 2007. **62**(11): p. 969-74.
38. Redline, S., V.K. Kapur, M.H. Sanders, S.F. Quan, D.J. Gottlieb, D.M. Rapoport, W.H. Bonekat, P.L. Smith, J.P. Kiley, and C. Iber, *Effects of varying approaches for identifying respiratory disturbances on sleep apnea assessment.* Am J Respir Crit Care Med, 2000. **161**(2 Pt 1): p. 369-74.
39. Polotsky, V.Y., J. Li, N.M. Punjabi, A.E. Rubin, P.L. Smith, A.R. Schwartz, and C.P. O'Donnell, *Intermittent hypoxia increases insulin resistance in genetically obese mice.* J Physiol, 2003. **552**(Pt 1): p. 253-64.
40. Somers, V.K., M.E. Dyken, M.P. Clary, and F.M. Abboud, *Sympathetic neural mechanisms in obstructive sleep apnea.* J Clin Invest, 1995. **96**: p. 1897-1904.
41. Tasali, E., R. Leproult, D.A. Ehrmann, and E. Van Cauter, *Slow-wave sleep and the risk of type 2 diabetes in humans.* Proc Natl Acad Sci U S A, 2008. **105**(3): p. 1044-9.

42. Spiegel, K., K. Knutson, R. Leproult, E. Tasali, and E. Van Cauter, *Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes*. J Appl Physiol, 2005. **99**(5): p. 2008-19.
43. Spiegel, K., R. Leproult, and E. Van Cauter, *Impact of sleep debt on metabolic and endocrine function*. Lancet, 1999. **354**: p. 1435-1439.
44. Ayas, N.T., D.P. White, W.K. Al-Delaimy, J.E. Manson, M.J. Stampfer, F.E. Speizer, S. Patel, and F.B. Hu, *A prospective study of self-reported sleep duration and incident diabetes in women*. Diabetes Care, 2003. **26**(2): p. 380-4.
45. Kawakami, N., N. Takatsuka, and H. Shimizu, *Sleep disturbance and onset of type 2 diabetes*. Diabetes Care, 2004. **27**(1): p. 282-3.
46. Nilsson, P.M., M. Roost, G. Engstrom, B. Hedblad, and G. Berglund, *Incidence of diabetes in middle-aged men is related to sleep disturbances*. Diabetes Care, 2004. **27**(10): p. 2464-9.
47. Mallon, L., J.E. Broman, and J. Hetta, *High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population*. Diabetes Care, 2005. **28**(11): p. 2762-7.
48. Meisinger, C., M. Heier, and H. Loewel, *Sleep disturbance as a predictor of type 2 diabetes mellitus in men and women from the general population*. Diabetologia, 2005. **48**(2): p. 235-41.
49. Yaggi, H.K., A.B. Araujo, and J.B. McKinlay, *Sleep duration as a risk factor for the development of type 2 diabetes*. Diabetes Care, 2006. **29**(3): p. 657-61.

50. Marshall, N.S., K.K. Wong, C.L. Phillips, P.Y. Liu, M.W. Knuiman, and R.R. Grunstein, *Is sleep apnea an independent risk factor for prevalent and incident diabetes in the Busselton Health Study?* J Clin Sleep Med, 2009. **5**(1): p. 15-20.
51. Gerstein, H.C., M.E. Miller, R.P. Byington, D.C. Goff, Jr., J.T. Bigger, J.B. Buse, W.C.ushman, S. Genuth, F. Ismail-Beigi, R.H. Grimm, Jr., J.L. Probstfield, D.G. Simons-Morton, and W.T. Friedewald, *Effects of intensive glucose lowering in type 2 diabetes.* N Engl J Med, 2008. **358**(24): p. 2545-59.
52. Patel, A., S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, S. Heller, L. Liu, G. Mancia, C.E. Mogensen, C. Pan, N. Poulter, A. Rodgers, B. Williams, S. Bompont, B.E. de Galan, R. Joshi, and F. Travert, *Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.* N Engl J Med, 2008. **358**(24): p. 2560-72.
53. Newman, A.B., G. Foster, R. Givelber, F.J. Nieto, S. Redline, and T. Young, *Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study.* Arch Intern Med, 2005. **165**(20): p. 2408-13.
54. Peppard, P., T. Young, M. Palta, J. Dempsey, and J. Skatrud, *Longitudinal study of moderate weight change and sleep-disordered breathing.* JAMA, 2000. **284**(23): p. 3015-3021.

Figure legends

Figure 1. Participant flow diagram

Figure 2. Adjusted mean hemoglobin A1c (HbA1c) values for patients with no, mild, moderate and severe OSA. Data were adjusted for age, gender, race, BMI, number of diabetes medications, level of exercise, years of diabetes and total sleep time on PSG. Bars represent standard errors.

Table 1. Sample characteristics: Diabetic patients (n=60) according to OSA status (AHI≥5)

Characteristic	All patients (n=60)	Patients without OSA (n=14)	Patients with OSA (n=46)	p value †
Age	57.0 ± 9.2	52.4 ± 7.6	58.4 ± 9.2	0.03
Male gender (%)	45	43	46	0.85
Race (%)				
African American	58	64	57	0.61
White	42	36	43	
BMI (kg/m ²)	33.8 ± 7.7	28.9 ± 5.8	35.3 ± 7.6	0.005
Waist circumference (inch) *	43.0 ± 6.6	39.8 ± 5.6	43.9 ± 6.6	0.05
HbA1c (%)	7.7 ± 1.8	7.2 ± 1.4	7.8 ± 1.9	0.28
Diabetes diagnosis (yrs)	9.6 ± 8.0	9.9 ± 9.0	9.6 ± 7.8	0.91
Diabetic complications (%) *	55	21	65	0.004
Diabetic medications (%) *				
Insulin	35	50	30	0.18
Oral hypoglycemic	76	71	78	0.60
Incretin-based	20	14	22	0.54
Exercise (%) *	67	79	63	0.28
Hypertension (%) *	70	64	72	0.59
Depression (%) *	35	21	39	0.22
Snoring *	33	32	21	0.42

Abbreviations: OSA=obstructive sleep apnea defined by 5 or more obstructive apneas and hyponeas per hour of sleep; BMI=body mass index (calculated as weight in kilograms divided by height in meters squared); HbA1c=hemoglobin A1c.

Data are given as mean ± SD or percentage.

* Data for waist circumference are reported in n=58; Presence of diabetic complications is based on self-report of one or more of the following: retinopathy, nephropathy, neuropathy, coronary artery or peripheral vascular disease; use of all diabetic medications are dichotomous variables (yes vs. no) by self-report; use of oral hypoglycemic agents is defined as use of at least one of the following medications: metformin, sulfonylurea, thiazolidinedione; exercise is a dichotomous variables (yes vs. no) based on self-report of exercising at least one to two times per week; the presence of hypertension is based on either self-report and/or use of medications; presence of snoring is by self report using Berlin Questionnaire.

† p values for unadjusted comparisons between patients with and without OSA are determined by t-test for continuous variables or Pearson's χ^2 test for categorical variables.

Table 2. Sleep characteristics: Diabetic patients (n=60) according to OSA status(AHI≥5)

Characteristic	All patients (n=60)	Patients without OSA (n=14)	Patients with OSA (n=46)	p value †
Actigraphy				
Sleep duration (hr) *	6.1 ± 1.2	5.7 ± 1.0	6.2 ± 1.3	0.18
Polysomnography				
Total sleep time (hr)	6.6 ± 1.1	7.2 ± 1.1	6.5 ± 1.0	0.02
Sleep efficiency (%)	83.1 ± 11.6	89.7 ± 7.7	81.1 ± 11.9	0.01
Sleep latency (min)	14.9 ± 18.6	9.3 ± 7.8	16.7 ± 20.5	0.19
Wake after sleep onset (min)	66.1 ± 50.0	42.0 ± 34.0	73.5 ± 52.0	0.04
REM (%)	22.3 ± 7.8	27.0 ± 7.2	20.9 ± 7.5	0.01
Stage 1 sleep (%)	8.5 ± 5.3	6.1 ± 2.4	9.2 ± 5.7	0.06
Stage 2 sleep (%)	62.9 ± 8.7	59.0 ± 9.0	64.1 ± 8.3	0.06
Slow wave sleep (%)	6.4 ± 7.8	7.9 ± 8.6	5.9 ± 7.5	0.40
Microarousal index (per hour of sleep)	25.6 ± 13.4	20.1 ± 10.7	27.3 ± 13.8	0.07
Total AHI (per hour of sleep)	15.2 ± 14.8	2.0 ± 1.2	19.2 ± 14.8	<0.0001
REM AHI (per hour of sleep)	27.3 ± 21.0	3.4 ± 3.4	34.6 ± 18.5	0.003
Total obstructive events	96.5 ± 89.1	14.8 ± 9.1	121.3 ± 87.7	<0.0001
Number of obstructive events in REM sleep	36.5 ± 33.9	5.9 ± 4.6	45.8 ± 33.5	<0.0001
Total central events	1.7 ± 3.8	0.8 ± 1.4	2.0 ± 4.2	0.30
Total ODI (per hour of sleep)	11.0 ± 12.0	1.1 ± 0.6	14.0 ± 12.2	0.0002
REM ODI (per hour of sleep)	22.1 ± 18.2	2.3 ± 2.2	28.2 ± 16.6	< 0.0001
Total number of desaturations ≥ 3%	69.7 ± 71.5	8.0 ± 4.8	88.5 ± 71.8	0.0001
Number of desaturations ≥ 3% in REM sleep	29.1 ± 28.3	3.9 ± 2.6	36.7 ± 28.1	<0.0001

Abbreviations: OSA=obstructive sleep apnea defined by 5 or more obstructive apneas and hyponeas per hour of sleep; AHI=apnea-hypopnea index; REM=rapid eye movement; ODI=oxygen desaturation index.

Data are given as mean ± SD.

* Data for sleep duration measured by wrist actigraphy are reported in n=59.

† p values for unadjusted comparisons between patients with and without OSA are determined by t-test for continuous variables.

Figure-1




Figure-2




Figure-2